Author:
Bellati Filippo,Napoletano Chiara,Gasparri Maria Luisa,Ruscito Ilary,Marchetti Claudia,Pignata Sandro,Tomao Federica,Benedetti Panici Pierluigi,Nuti Marianna
Reference89 articles.
1. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders;Presta;Cancer Res,1997
2. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer;Matulonis;J Clin Oncol,2009
3. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors;Moore;Ann Oncol,2005
4. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer;Friedlander;Gynecol Oncol,2010
5. Phase I and pharmacokinetic study of the novel VEGF-directed fusion protein, afl ibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer;Coleman;J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed),2009